Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

[1]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  R. Salem,et al.  Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer , 2016, British Journal of Cancer.

[3]  S. Jeffrey,et al.  Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility , 2015, Clinical Cancer Research.

[4]  K. Nouso,et al.  Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.

[5]  E. Giovannetti,et al.  Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer , 2015, Clinical Cancer Research.

[6]  M. Borad,et al.  Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Li,et al.  LRH1 promotes pancreatic cancer metastasis. , 2014, Cancer letters.

[8]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[9]  D Saur,et al.  Oncogenic KRAS signalling in pancreatic cancer , 2014, British Journal of Cancer.

[10]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[11]  Y. Yatabe,et al.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer , 2013, Journal of Gastroenterology.

[12]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[13]  D. V. Von Hoff,et al.  Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer , 2013, Clinical Cancer Research.

[14]  B. Esterni,et al.  BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Kam M. Hui,et al.  MiR-214 Targets β-Catenin Pathway to Suppress Invasion, Stem-Like Traits and Recurrence of Human Hepatocellular Carcinoma , 2012, PloS one.

[16]  N. Sasahira,et al.  A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study , 2012, British Journal of Cancer.

[17]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[18]  Ben H. Park,et al.  Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.

[19]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[20]  Robert Schmieder,et al.  Abstract B247: The MEK inhibitor BAY 869766 inhibits tumor growth and metastatic spread, prolongs the survival and acts synergistically with standard of care drugs in models of hepatocellular carcinoma and pancreatic cancer. , 2011 .

[21]  Joon-Oh Park,et al.  Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy , 2011, Molecular Cancer Therapeutics.

[22]  D. Birnbaum,et al.  Genome profiling of pancreatic adenocarcinoma , 2011, Genes, chromosomes & cancer.

[23]  M. Tsao,et al.  Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer , 2010, Cancer.

[24]  Robert Schmieder,et al.  151 Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer , 2010 .

[25]  M. Hebrok,et al.  KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma , 2010, Nature Reviews Cancer.

[26]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[27]  C. Paweletz,et al.  A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors , 2010, BMC Medical Genomics.

[28]  Sylvain Meloche,et al.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy , 2010, Journal of hematology & oncology.

[29]  R. Hamatake,et al.  RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. , 2009, Cancer research.

[30]  A. Adjei,et al.  Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy , 2008, Clinical Cancer Research.

[31]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[34]  Frank Diehl,et al.  BEAMing up for detection and quantification of rare sequence variants , 2006, Nature Methods.

[35]  F. Barlesi,et al.  Gemcitabine‐induced severe pulmonary toxicity , 2004, Fundamental & clinical pharmacology.

[36]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. V. Von Hoff,et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[39]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[40]  L. Jian-hua,et al.  Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic Cancer , 2010 .